The National Institute for Health and Care Excellence

Changes to NICE’s cost-effectiveness thresholds confirmed

The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
The National Institute for Health and Care Excellence

Seven digital platforms supporting at home cardiac rehab given conditional recommendations

Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...
National Institute for Health and Care Excellence

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after ...
National Institute for Health and Care Excellence

Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is ...
National Institute for Health and Care Excellence

Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment

Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies. EVA guidance rapidly provides ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...
National Institute for Health and Care Excellence

Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care

We have moved Diagnostics guidance 35 to become HealthTech guidance 508. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Otitis media (acute): antimicrobial prescribing

This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be ...